

REVISED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number  
WO 2003/082853 A1

(51) International Patent Classification<sup>7</sup>: **C07D 401/04**,  
403/04, 401/14, 403/14, 413/14, A61K 31/404, 31/4427,  
31/495, A61P 25/28, 25/00, 3/10, 15/16

(21) International Application Number:  
PCT/SE2003/000508

(22) International Filing Date: 28 March 2003 (28.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0200979-3 28 March 2002 (28.03.2002) SE

(71) Applicant (for all designated States except US): AS-  
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BERG**, Ste-  
fan [SE/SE]; AstraZeneca R & D Södertälje, S-151  
85 Södertälje (SE). **HELLBERG**, Sven [SE/SE]; As-  
traZeneca R & D Södertälje, S-151 85 Södertälje (SE).  
**NYLÖF**, Martin [SE/SE]; AstraZeneca R & D Södertälje,  
S-151 85 Södertälje (SE). **XUE**, Yafeng [CN/SE]; As-  
traZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; As-  
traZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,

SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU,  
SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,  
UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR),  
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report


(88) Date of publication of the revised international search  
report: 6 May 2004

(15) Information about Correction:


see PCT Gazette No. 19/2004 of 6 May 2004, Section II

[Continued on next page]

(54) Title: NEW COMPOUNDS



(Ia)



(Ib)

(57) Abstract: The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.